Cliff Asness’s Fulcrum Therapeutics FULC Stock Holding History

Cliff Asness’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.04M	Buy	1,103,261 +560,096	+103%	+$3.41M	﹤0.01%	2139
2026 Q1	$4.17M	Buy	543,165 +527,663	+3,404%	+$4.89M	﹤0.01%	1864
2025 Q4	$175K	Buy	+15,502	New	+$158K	﹤0.01%	3385
2025 Q3	–	Sell	-18,053	Closed	-$124K	–	3505
2025 Q2	$124K	Buy	18,053 +445	+3%	+$2.38K	﹤0.01%	3145
2025 Q1	$50.7K	Sell	17,608 -28,033	-61%	-$103K	﹤0.01%	3081
2024 Q4	$215K	Sell	45,641 -52,835	-54%	-$195K	﹤0.01%	2648
2024 Q3	$352K	Buy	+98,476	New	+$731K	﹤0.01%	2320
2022 Q3	–	Sell	-13,966	Closed	-$68K	–	2243
2022 Q2	$68K	Buy	+13,966	New	+$136K	﹤0.01%	2118
2022 Q1	–	Sell	-14,024	Closed	-$248K	–	2241
2021 Q4	$248K	Buy	+14,024	New	+$278K	﹤0.01%	2029

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cliff Asness's FULC Position: Q2 2026 in Review

Cliff Asness increased its Fulcrum Therapeutics (FULC) stake by 103% in Q2 2026, buying an estimated $3.41M and bringing the position to 1,103,261 shares worth $4.04M. The position accounts for ﹤0.01% of the portfolio, ranked #2139.

Cliff Asness first reported a position in FULC in Q4 2021 and has held it in 9 quarters since. The position peaked at $4.17M in Q1 2026. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

Cliff Asness held 1,103,261 shares of Fulcrum Therapeutics worth $4.04M as of Q2 2026.
Cliff Asness bought 560,096 Fulcrum Therapeutics shares in Q2 2026, an estimated $3.41M.
Fulcrum Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #2139 holding.
Cliff Asness first reported a position in Fulcrum Therapeutics in Q4 2021 and has held it in 9 quarters since.
Cliff Asness's Fulcrum Therapeutics position peaked at $4.17M in Q1 2026.
154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.